Loading
RANK ligand is the signal that tells bone-dissolving cells to get to work. Cancers in the bone hijack it; denosumab blocks it to prevent fractures and other bone complications. This dossier gathers the 1 product (1 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
RANKL also functions in lymph node development and mammary gland biology; RANK signalling in breast epithelium has been linked to progestin-driven and BRCA1-associated tumorigenesis.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 91% | IHC, RANKL in 10 of 11 primary prostate cancer specimens (heterogeneous staining) | Brown 2001 (Urology); 28 patients studied overall, all bone metastases were RANKL-immunoreactive and the fraction of positive tumour cells was higher in bone metastases than in primaries | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Antibody 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
PEACE-3 (EORTC 1333) NCT02194842 | 3 | Positive | Asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer with bone metastases: enzalutamide 160 mg daily alone against enzalutamide with six monthly injections of radium-223 at 55 kBq/kg, with bone-protecting agents made mandatory for all patients from March 2018, with radiological progression-free survival as the primary endpoint | Median overall survival 38.2 months with enzalutamide plus radium-223 against 32.6 months with enzalutamide alone (hazard ratio 0.76, 95 percent confidence interval 0.60 to 0.96, p=0.0096); radiological progression-free survival hazard ratio 0.71 (0.57 to 0.89). Bone-protecting agents mandatory. | |
| 2 | Recruiting | A Multicenter, Randomized, Double-Blind, Positively Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"RANK ligand" OR ABSTRACT:"RANK ligand" OR TITLE:"RANKL" OR ABSTRACT:"RANKL" OR TITLE:"TNFSF11" OR ABSTRACT:"TNFSF11") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RANK ligand (RANKL), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/rankl.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rankl.json. Licence CC BY-NC 4.0.